The FDA’s Infection
Want to understand the challenge facing the next FDA chief? Look at how the agency handles antibiotics.
Related Articles
MIT Shut Down Internal Grant Database After It Was Used to Research School’s Israel Ties
Amid Gaza protests, a report from MIT Coalition for Palestine details research funded by Israel on drone swarms and underwater surveillance.
Former Trump health official: Medicare should cover Wegovy — but not negotiate its price
Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price…
Medicare announces plan to negotiate prices of diabetes, weight-loss drugs
The expensive weight loss drug Wegovy is among 15 whose prices will soon be negotiated by Medicare.
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been…
As researchers push for a type 1 diabetes cure, Sana Biotechnology provides a nudge forward
As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, clinical trial data.
As researchers push for a type 1 diabetes cure, Sana Biotechnology provides a nudge forward
As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, clinical trial data.
At JPM, biotech industry expresses excitement — and some anxiety — about therapies from China
Are we entering a world in which all of the exciting new therapeutics come from China? At #JPM25, that question and variations of it were…
Medicare director, at JPM conference, gives tips on how to lead the nation’s largest payer
The current head of the Center for Medicare has advice for her successor: “Engaging everyone in the ecosystem” is the foundation of good policymaking.
At JPM, biotech industry expresses excitement — and some anxiety — about therapies from China
Are we entering a world in which all of the exciting new therapeutics come from China? At #JPM25, that question and variations of it were…
Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there were reasons for concern.